Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus PHOSPHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus PHOSPHOTOPE.
MACROTEC vs PHOSPHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical